Many PD-1 and CTLA-4 inhibitors, either as a single reagent, or in combination, have been permitted or tested in clinical trials by the United States Food and Drug Administration for the treatment of metastatic melanoma and other advanced cancers. The gene discussed is CTLA4; the disease is cancer.